Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Core Insights - Regeneron Pharmaceuticals announced positive topline data from a Phase 3 trial of olatorepatide, a dual GLP-1/GIP receptor agonist, showing up to 19% body-weight loss in patients at week 48 [1][2] - The trial, conducted by Hansoh Pharmaceutical, involved 604 adults in China and met its co-primary endpoints, demonstrating significant weight loss compared to placebo [2][6] - Olatorepatide exhibited favorable gastrointestinal tolerability, with low rates of nausea and vomiting [3] Group 1: Trial Details - The Phase 3 trial was randomized, double-blind, and placebo-controlled, conducted across 33 clinical sites in mainland China [2][6] - Participants were randomized into four cohorts receiving either 5 mg, 10 mg, or 15 mg of olatorepatide or placebo, evaluated over 48 weeks [2][6] - Up to 97% of participants treated with olatorepatide achieved at least 5% weight loss at week 48 [2] Group 2: Company Strategy and Pipeline - Regeneron holds exclusive rights for clinical development and commercialization of olatorepatide outside Greater China, while Hansoh retains rights within Greater China [1][5] - The company is advancing into a global Phase 3 registrational program later this year, with detailed trial data expected to be presented at an upcoming medical meeting [1][4] - Regeneron is focused on developing a pipeline that addresses obesity and related metabolic diseases, aiming to enhance the quality of weight reduction [7]